Xencor jumps after bispecific antibody deal with Novartis

Xencor Inc. (NASDAQ:XNCR) gained $4.02 (32%) to $16.56 on Tuesday after granting Novartis AG (NYSE:NVS; SIX:NOVN) rights to develop bispecific antibodies using Xencor's

Read the full 237 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE